Tag: CLN3
THERANEXUS: Encouraging preliminary results at 6 months in the phase 1/2 study of Batten-1 in Batten disease (CLN3) – 06/14/2023 at 07:30
Reduction after 6 months of treatment of neurofilaments, a biomarker of neuronal death Stabilization of motor symptoms for treated patients compared to an expected deterioration according to the natural history…
THERANEXUS: New progress for the Batten-1 Program of Theranexus and the BBDF foundation in the juvenile form of Batten disease (CLN3) – 01/05/2023 at 18:00
Lyon, France – Austin, Texas, United States – January 5, 2023 – 6:00 p.m. CET – Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer…